Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioiberica Joins a European Project to Develop Treatments for Complex Wounds
Details : Aim is to develop innovative multifunctional biomaterials to heal wounds using affordable EU-based manufacturing technologies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KABP022,KABP023,KABP033
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Zambon Group SpA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.
Product Name : AB21
Product Type : Probiotic
Upfront Cash : Inapplicable
February 21, 2022
Lead Product(s) : KABP022,KABP023,KABP033
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Zambon Group SpA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Grifols To Begin Clinical Trial To Evaluate Plasma-derived COVID-19 Drug - Quick Facts
Details : Grifols will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the di...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company has started production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sesderma Labs Produces Lactyferrin to Counter the COVID-19 Strain
Details : More than 75 patients affected by COVID-19 have been successfully treated with Lactyferrin, to date with moderate to severe clinical features.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2020
Lead Product(s) : Genistein
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RUTI Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RUTI® vaccine is administered by subcutaneous injection, is safe and is in advanced clinical stages in India and Ukraine for the treatment of tuberculosis and antibiotic-resistant tuberculosis, and also as an enhancer of the anticancer response in bladd...
Product Name : RUTI
Product Type : Vaccine
Upfront Cash : Inapplicable
August 04, 2020
Lead Product(s) : RUTI Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Grifols will volunteer its expertise and resources in the areas of plasma collection using its network of plasma donor centers; test and qualify donors in conjunction with other health agencies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Collaboration